Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

Launched by MANSOURA UNIVERSITY · Mar 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called dapagliflozin in adults with chronic kidney disease (CKD) who also have anemia, a condition where you don't have enough healthy red blood cells. Dapagliflozin is usually used to help manage type 2 diabetes, but recent research suggests it might also help improve hemoglobin levels in patients with CKD. The trial aims to see if dapagliflozin can effectively raise hemoglobin levels, which could be beneficial for those struggling with anemia due to their kidney condition.

To participate in this trial, you must be an adult aged 18 or older, have CKD stage III or IV, and have anemia with a hemoglobin level below 11.5 g/dL. Additionally, you should already be receiving treatment that helps stimulate the production of red blood cells. However, if your anemia is caused by other conditions, or if you have certain health issues like severe infections or recent heart problems, you may not be eligible. Participants can expect to receive the study medication and be monitored regularly to assess its effects on their anemia. This trial is currently recruiting, and it welcomes all genders.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • 1. Adults aged ≥ 18 years with CKD stage III or IV.
• • 2. Patients with anemia of CKD and a hemoglobin level \< 11.5 g/dL
• • 3. Patients are receiving erythropoiesis-stimulating agent therapy.
• • Exclusion criteria
• • 1. Anemia due to causes other than chronic kidney disease, such as pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes.
• • 2. Patients with severe ketosis, diabetic coma, severe infection, perioperative complications, or severe trauma.
• • 3. Patients with acute heart failure, acute myocardial infarction, or stroke occurring within 6 months before enrollment in the trial.
• • 4. Patients with current malignancies or a history of malignancy within the past 2 years.
• • 5. Diagnosed with pure red cell aplasia.
• • 6. Patients with severe gastrointestinal bleeding.
• • 7. Pregnant or lactating females.